CN114007644A - 抗cd117抗体及其用途 - Google Patents

抗cd117抗体及其用途 Download PDF

Info

Publication number
CN114007644A
CN114007644A CN202080044160.XA CN202080044160A CN114007644A CN 114007644 A CN114007644 A CN 114007644A CN 202080044160 A CN202080044160 A CN 202080044160A CN 114007644 A CN114007644 A CN 114007644A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044160.XA
Other languages
English (en)
Chinese (zh)
Inventor
R.帕尔乔杜里
A.博伊塔诺
M.库克
B.R.皮尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of CN114007644A publication Critical patent/CN114007644A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080044160.XA 2019-04-24 2020-04-23 抗cd117抗体及其用途 Pending CN114007644A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838264P 2019-04-24 2019-04-24
US62/838,264 2019-04-24
US201962841733P 2019-05-01 2019-05-01
US62/841,733 2019-05-01
PCT/US2020/029648 WO2020219770A1 (en) 2019-04-24 2020-04-23 Anti-cd117 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN114007644A true CN114007644A (zh) 2022-02-01

Family

ID=72941829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044160.XA Pending CN114007644A (zh) 2019-04-24 2020-04-23 抗cd117抗体及其用途

Country Status (7)

Country Link
US (1) US20220177575A1 (cg-RX-API-DMAC10.html)
EP (1) EP3958902A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022529726A (cg-RX-API-DMAC10.html)
CN (1) CN114007644A (cg-RX-API-DMAC10.html)
AU (1) AU2020261405A1 (cg-RX-API-DMAC10.html)
CA (1) CA3134319A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020219770A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533960A (zh) * 2011-05-12 2014-01-22 英克隆有限责任公司 c-KIT抗体及其用途
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533960A (zh) * 2011-05-12 2014-01-22 英克隆有限责任公司 c-KIT抗体及其用途
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides

Also Published As

Publication number Publication date
EP3958902A4 (en) 2023-01-25
WO2020219770A1 (en) 2020-10-29
AU2020261405A1 (en) 2021-12-23
US20220177575A1 (en) 2022-06-09
JP2022529726A (ja) 2022-06-23
CA3134319A1 (en) 2020-10-29
EP3958902A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
JP7641452B2 (ja) Cd117+細胞を減少させるための組成物及び方法
US11572411B2 (en) Anti-CD117 antibodies and conjugates
JP7669269B2 (ja) 抗-cd45抗体及びそのコンジュゲート
JP7716399B2 (ja) 抗-cd45抗体及びそのコンジュゲート
US20220177575A1 (en) Anti-cd117 antibodies and uses thereof
CN119857155A (zh) 用于耗尽cd5+细胞的组合物和方法
JP2021500375A5 (cg-RX-API-DMAC10.html)
JP2022529726A5 (cg-RX-API-DMAC10.html)
CN111670200A (zh) 用于耗尽cd2+细胞的组合物和方法
US20220177578A1 (en) Anti-cd117 antibodies and uses thereof
JP2022529727A5 (cg-RX-API-DMAC10.html)
CN112154152A (zh) 抗cd252抗体、缀合物和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220201